Mutations, Hormone Therapy (HRT) and Venous Thromboembolism

NCT00005515 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2016-02-10

No results posted yet for this study

Summary

To assess the interaction between hormone replacement therapy and the prothrombotic mutations, Factor V Leiden and the recently described prothrombin mutation (20210A) on the incidence of venous thromboembolism (VTE) in a population-based case-control study conducted at Group Health Cooperative of Puget Sound (GHC).

Conditions

Sponsors & Collaborators

Principal Investigators

  • Bruce Psaty · University of Washington

Eligibility

Min Age
30 Years
Max Age
89 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-09-30
Completion
2003-08-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005515 on ClinicalTrials.gov